急性冠脉综合征患者经皮冠状动脉介入治疗围手术期的胃肠外抗凝治疗进展  

Perioperative Parenteral Anticoagulant Therapy in Patients with Acute Coronary Syndrome During Percutaneous Coronary Intervention

作　　者：陈威锟 刘远辉[1] 甄慈恩 张业燊 范华林 何鹏程[1] 谭宁[1] 吴君[1] CHEN Weikun;LIU Yuanhui;ZHEN Cien;ZHANG Yeshen;FAN Hualin;HE Pengcheng;TAN Ning;WU Jun(Department of Cardiology,Guangdong Cardiovascular Institute,Guangdong Provincial People’s Hospital,Guangzhou 510080,Guangdong,China;School of Medicine of South China University of Technology,Guangzhou 510080,Guangdong,China)

机构地区：[1]广东省心血管病研究所、广东省人民医院心内科,广东广州510080 [2]华南理工大学医学院,广东广州510080

出　　处：《心血管病学进展》2023年第1期35-38,43,共5页Advances in Cardiovascular Diseases

基　　金：广东省人民医院“双青人才计划——优秀青年人才”项目(KJ012019095)。

摘　　要：经皮冠状动脉介入治疗(PCI)是急性冠脉综合征的主要治疗方式。PCI围手术期抗血小板治疗联合抗凝治疗减少了急性冠脉综合征患者血栓事件的发生,同时也使出血风险随之增加,近年来有研究提示围手术期胃肠外抗凝治疗收益与风险需重新评估。现综述PCI围手术期胃肠外抗凝治疗常用药物及其优缺点,并阐述围手术期胃肠外抗凝治疗新研究进展。Percutaneous coronary intervention(PCI)is the main treatment for acute coronary syndrome.PCI perioperative antiplatelet combined anticoagulant therapy reduces the occurrence of thrombotic events in patients with acute coronary syndrome and increases the risk of bleeding.In recent years,studies have suggested that the benefits and risks of perioperative parenteral anticoagulant therapy need to be re-evaluated.In this paper,we will review the advantages and disadvantages of commonly used perioperative parenteral anticoagulants for PCI,and describe the new research progress of perioperative parenteral anticoagulants.

关 键 词：急性冠脉综合征 经皮冠状动脉介入治疗 胃肠外抗凝治疗 

分 类 号：R541.4[医药卫生—心血管疾病]